MicroRNA‑383‑5p predicts favorable prognosis and inhibits the progression of diffuse large B‑cell lymphoma

  • Authors:
    • Li-Yan Chen
    • Bi-Qing Han
    • Xiao-Min Zhang
    • Xing-Bao Yu
    • Dan-Dan Yao
    • Li-Qian Yu
  • View Affiliations

  • Published online on: May 6, 2021     https://doi.org/10.3892/ol.2021.12776
  • Article Number: 515
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The roles of microRNA (miRNA/miR)‑383‑5p have been reported in several malignancies, including breast cancer, gastric cancer, ovarian cancer and lung adenocarcinoma. However, its function in diffuse large B‑cell lymphoma (DLBCL) remains unclear. Thus, the present study aimed to investigate the role of miR‑383‑5p in DLCBL. Reverse transcription‑quantitative PCR analysis was performed to detect miR‑383‑5p expression in 80 paired tissue samples from patients with DLBCL and control subjects, as well as related cancer cell lines. Kaplan‑Meier survival analysis was performed, and the prognostic value of miR‑383‑5p was determined via Cox regression analysis. Furthermore, the association between miR‑383‑5p expression and the clinicopathological characteristics of patients with DLBCL was investigated. The Cell Counting Kit‑8, crystal violet staining and Transwell assays were performed to assess the effects of miR‑383‑5p on cell proliferation and invasion, respectively. The results demonstrated that miR‑383‑5p expression was upregulated in human DLBCL tissues and cell lines. In addition, miR‑383‑5p expression was closely associated with clinical stage and extranodal invasion in patients with DLBCL. Notably, high miR‑383‑5p expression was able to predict a favorable clinical prognosis in patients with DLBCL. Furthermore, overexpression of miR‑383‑5p significantly inhibited the proliferation and invasion of DLBCL cells, the effects of which were reversed following miR‑383‑5p knockdown. Taken together, the results of the present study suggest that miR‑383‑5p may predict favorable prognosis, and thus may be used as a prognostic biomarker for patients with DLBCL. In addition, miR‑383‑5p appears to play critical roles in inhibiting the proliferation and invasion of DLBCL cells, and thus may be used as a potential therapeutic target in patients with DLBCL.
View Figures
View References

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen L, Han B, Zhang X, Yu X, Yao D and Yu L: MicroRNA‑383‑5p predicts favorable prognosis and inhibits the progression of diffuse large B‑cell lymphoma. Oncol Lett 22: 515, 2021
APA
Chen, L., Han, B., Zhang, X., Yu, X., Yao, D., & Yu, L. (2021). MicroRNA‑383‑5p predicts favorable prognosis and inhibits the progression of diffuse large B‑cell lymphoma. Oncology Letters, 22, 515. https://doi.org/10.3892/ol.2021.12776
MLA
Chen, L., Han, B., Zhang, X., Yu, X., Yao, D., Yu, L."MicroRNA‑383‑5p predicts favorable prognosis and inhibits the progression of diffuse large B‑cell lymphoma". Oncology Letters 22.1 (2021): 515.
Chicago
Chen, L., Han, B., Zhang, X., Yu, X., Yao, D., Yu, L."MicroRNA‑383‑5p predicts favorable prognosis and inhibits the progression of diffuse large B‑cell lymphoma". Oncology Letters 22, no. 1 (2021): 515. https://doi.org/10.3892/ol.2021.12776